ATS 2024 Final Program

Click on the session title to view the speakers

56

SUNDAY • MAYs 19

P857 Analyzing Outcomes in COPD Patients With Coexistent Interstitial Lung Disease Admitted for COPD Exacerbation: A Population-based Study Using the National Inpatient Sample P858 Exploring the Influence of Protein-energy Malnutrition in Patients With Interstitial Lung Disease: A Nationwide Inpatient Analysis P859 Sexual Dysfunction Is Common in Patients With Fibrotic Interstitial Lung Disease: A Mixed Methods Study P860 Long-term Air Pollution Exposure Is Associated With Increased Severity of Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry P861 Clinical Impact of Small Airway Dysfunction in Idiopathic Pulmonary Fibrosis P862 3-month Change in Hyperpolarized 129 Xe MRI Membrane Uptake Predicts 6-month Change in Lung Function in Patients With Idiopathic Pulmonary Fibrosis P863 Impact of COVID-19 on Exacerbations and Mortality in Interstitial Lung Disease at Long-term Follow-up: A Nationwide Population-based Cohort Study P864 Small Airways Disease on Computed Tomography Is Associated With Interstitial Lung Abnormality Presence and Progression P865 Multidimensional Severity Index to Pneumoconiosis: The BCDS Score P866 Survival in Familial Pulmonary Fibrosis According to the Phenotype P867 The Characteristics and Outcomes of Interstitial Lung Disease With Preserved Pulmonary Function P868 Incremental Burden of Pulmonary Hypertension Among Patients With Non-connective Tissue Disease-related Interstitial Lung Disease in the Real-world Setting P869 Incremental Burden of Pulmonary Hypertension Among Patients With Connective Tissue Disease-related Interstitial Lung Disease in the Real-world Setting P870 Interstitial Lung Disease as an Emerging Contributor to Mortality in Patients With Inflammatory Bowel Disease: An Epidemiologic Analysis

P871 Malnutrition Associated With Worse Outcomes in Patients Admitted With Idiopathic Pulmonary Fibrosis Exacerbation P872 The Clinical Impact of Heart Failure With Preserved Ejection Fraction in Interstitial Lung Diseases P873 Post-operative Outcomes in Patients With Pulmonary Sarcoidosis in Relation to Lung Explant Pathology P874 How the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines Affect Our Understanding of Mortality in Non-IPF ILD P875 Significance of Pulmonary Vasculopathy in Idiopathic Pulmonary Fibrosis Diagnosed by Surgical Lung Biopsy P876 The Effect of Race on Diagnosis and Clinical Outcomes for Anti-synthetase Syndrome Associated Interstitial Lung Disease- A Single Center Study P877 Frailty, Sarcopenia, and Multimorbidity as Predictors of Adverse Outcomes in Older Veterans With Idiopathic Pulmonary Fibrosis on Antifibrotics P878 Pulmonary Complications and Bronchoscopy Utilization in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitor Therapy P879 Prevalence, Characteristics and Progression of Interstitial Lung Abnormalities in Patients With Lung Cancer Resection: A Single Center Report P880 Impact of Resources in Reducing Depression in Patients With Chronic Fibrosing Interstitial Lung Disease P881 The Prevalence and Risk Factors of Progressive Interstitial Lung Abnormalities in a Large Health Checkup Population in Japan P882 Exertional Hypoxemia Post COVID P883 A Comparison Between COVID-19 Patients With Underlying Connective-Tissue Disease Related Interstitial Lung Disease Versus Idiopathic Interstitial Lung Disease: A Nationwide Analysis 2019-2020 P884 Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes P885 Comparative Outcomes of Patients With Interstitial Lung Disease With and Without Atrial Fibrillation: A Nationwide Study From 2011-2018

ATS 2024 Conference Program • San Diego, CA